Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib.
Pu ChenJianling WangYao YaoYiping QuMeiju JiPeng Hou
Published in: Endocrine (2024)
mutation can accurately diagnose thyroid cancer. In addition, inhibition of DUSP5 improves the response of BRAF-mutant thyroid cancer cells to sorafenib.